InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 20, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
COVID-19Lymphocytopenia
Interventions
DRUG

CYT107

IM administration at 10µg/kg twice a week for three weeks and up to 7 administrations according to Hospital length of stay

DRUG

Placebo

Same number, volume and frequency of IM administration of saline

Trial Locations (2)

10065

Memorial sloan kettering, New York

77030

MD Anderson cancer center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Amarex Clinical Research

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Cancer Research Institute, New York City

OTHER

lead

Revimmune

INDUSTRY